Oct. 3, 2025
| Today’s news and insights for biopharma leaders
Wall Street analysts expect the subcutaneous version of Keytruda, which just launched this week, to help soften the blow when the original loses patent protection later this decade.
|
News roundup
The decision to clear another mifepristone generic sparked political backlash. Elsewhere, investors will pump up to $175 million into Ovid after the company reported early, but encouraging, data for a potential epilepsy drug.
|
UPDATED
Twelve biotechs raised funding rounds in September that involved the firms tracked by BioPharma Dive, the highest number in any month since January.
|
Explore why chromatography is a critical tool in pharma development and learn how to employ it effectively.
|
Deep Dive
Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.
|
Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.
|
|
Since 2022, Chinese companies account for 31% of the total global drug market. Learn how Western pharma companies can collaborate with China’s booming bioscience sector in this playbook.
|
|
From Our Library
Trendline
Supported by 10x Genomics
|
Survey Report
Custom content for Qiagen
|
Trendline
Supported by Catalent
|
| 
